AccessibilityHelpAbout Us
Zomedica logo

Zomedica(NYSEMKT) ZOM

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-90%
5 Year-85%
1 Year-1%
1 Month-7%
N/A
Zomedica last closing stock price
MetricPriceDate
Last closeUSD 0.082026-09-25
Zomedica stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.41%USD 0.082026-09-18
1 month-6.76%USD 0.092026-08-26
3 month-16.37%USD 0.102026-06-26
Year to date-21.38%USD 0.102025-12-31
1 year-0.56%USD 0.082025-09-25
3 year-52.94%USD 0.172023-09-26
5 year-84.55%USD 0.522021-09-24
Since inception-90.35%USD 0.832016-07-29

Zomedica Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$36.88M

Net Income (TTM)

-$18.95M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Mar 13, 2025

ZOM News

veterinarian works with dog

Why Shares of Zomedica Were Zooming Monday

James HalleyMar 20, 2023
People crowding around a computer.

2 Meme Stocks That Are Still Down 50% Since February 2021

David Jagielski, CPAAug 20, 2022
Frustrated people looking at a laptop.

2 Meme Stocks Investors Should Avoid at All Costs

David Jagielski, CPAApr 1, 2022
Veterinarian with a dog

Zomedica Stock Jumped Today. Is It a Buy?

Keith SpeightsFeb 28, 2022
Veterinarian with woman and dog

Why Zomedica Stock Is Soaring Today

Keith SpeightsFeb 28, 2022
vetcare

Why Zomedica Stock Soared 72.4% This Week

James HalleyFeb 17, 2022
zomedica

Why Shares of Zomedica Corp. Dropped 22.5% in December

James HalleyJan 4, 2022
People playing video games in a cafe.

3 Rookie Mistakes to Avoid Making in the Stock Market

David Jagielski, CPADec 29, 2021
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zomedica

Zomedica Corp. is a veterinary healthcare enterprise focused on developing innovative products for companion animals. The company specializes in point-of-care diagnostic tools and therapeutic solutions for various veterinary needs.

Products and Services
  • TRUFORMA platform for point-of-care diagnostics
  • PulseVet system for musculoskeletal conditions in animals
  • Collaborative agreements for cancer detection and pathogen detection systems
Growth Outlook
  • Revenue increased to $9.5 million in Q2 2026, up from $8.8 million in Q1 2026
  • Gross profit margin improved to 63.5% in Q2 2026
  • Strong cash position with $44.1 million in cash and short-term investments
Financial Highlights
  • Net income of -$3.8 million in Q2 2026, showing a reduction in losses
  • Current ratio of 6.43 indicates strong liquidity
  • Operating expenses decreased to $10.1 million in Q2 2026
Zomedica Corp. is positioned in the veterinary healthcare sector, focusing on the specific needs of clinical veterinarians. The TRUFORMA platform is a significant innovation, providing rapid diagnostic capabilities for canine and feline illnesses. The PulseVet system addresses musculoskeletal issues, enhancing treatment options for various animals. Collaborative agreements with companies like Celsee, Inc. and Seraph Biosciences, Inc. further expand Zomedica's product offerings and market reach. The growth outlook appears promising, with a notable increase in revenue and an improved gross profit margin. The company's strong cash position allows for continued investment in research and development, which is crucial for long-term success. Recent financial results indicate a reduction in net losses, suggesting operational improvements and effective cost management. Overall, Zomedica Corp. presents an intriguing opportunity within the veterinary healthcare market, driven by innovative products and a commitment to addressing the needs of veterinarians and their patients.
AI Generated • Sep 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

141

CEO

Larry C. Heaton, II

Website

www.zomedica.com

Headquarters

Ann Arbor, MI 48108, US

ZOM Financials

Key Financial Metrics (TTM)

Gross Margin

65.44%

Operating Margin

-56.28%

Net Income Margin

-51.39%

Return on Equity

-16.72%

Return on Capital

-72.65%

Return on Assets

-16.04%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$24.13M

Operating Income

-$20.75M

EBITDA

-$11.60M

Operating Cash Flow

-$13.37M

Capital Expenditure

$0.00

Free Cash Flow

-$13.37M

Cash & ST Invst.

$44.13M

Total Debt

$718.00K

Zomedica Performance Analysis

Zomedica annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 18,930,000358.0%
20232023-12-31USD 25,186,00033.0%
20242024-12-31USD 27,285,0008.3%
20252025-12-31USD 32,030,00017.4%
Zomedica sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.2%
Q42025-12-3129.4%
Q12026-03-31-16.0%
Q22026-06-308.1%
Zomedica annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.02-9.4%
20232023-12-31USD -0.04102.3%
20242024-12-31USD -0.0536.1%
20252025-12-31USD -0.0874.3%
Zomedica sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31100.0%
Q12026-03-31N/A
Q22026-06-3017.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2027YOY CHG

Revenue

$9.51M

+36.6%

Gross Profit

$6.04M

+29.5%

Gross Margin

63.51%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

144

N/A

Net Income

-$3.77M

+49.1%

EBITDA

-$4.08M

+25.3%

Quarterly Fundamentals

Name
Q2 2027YOY CHG

Total Cash

$44.13M

-24.0%

Total Debt

$718.00K

+4.5%

Accounts Receivable

$6.03M

+106.4%

Inventory

$6.05M

+6.7%

Long Term Debt

$0.00

N/A

Short Term Debt

$718.00K

+4.5%

Return on Assets

-16.04%

N/A

Return on Invested Capital

-19.01%

N/A

Free Cash Flow

-$2.55M

+53.1%

Operating Cash Flow

-$2.55M

+53.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OPTNOptiNose, Inc.
$9.60+0.00%
ZYNEZynerba Pharmaceuticals, Inc.
$1.30+2.36%
UPXIUpexi, Inc.
$1.23+5.13%
AADIAadi Bioscience, Inc.
$2.05-2.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About ZOM

What is the current price of Zomedica?

Zomedica is trading at N/A per share.

What is the 52-week range for Zomedica?

Over the past 52 weeks, Zomedica has traded between N/A and N/A.

How much debt does Zomedica have?

As of the most recent reporting period, Zomedica reported total debt of $1.83M.

How much cash does Zomedica have on hand?

Zomedica reported $7.19M in cash and cash equivalents in its most recent financial results.

What is Zomedica’s dividend yield?

Zomedica does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services